Pathophysiology and principles of management of the many faces of the acute vaso‐occlusive crisis in patients with sickle cell disease
- 31 October 2014
- journal article
- review article
- Published by Wiley in European Journal of Haematology
- Vol. 95 (2) , 113-123
Abstract
Effective management of sickle cell pain entails a thorough understanding of its pathophysiology and the pharmacogenomics of the opioids used to manage it. In recent years, there has been significant progress along these two lines. At the pathophysiologic level, there is evidence that the severity and frequency of painful stimuli modulate their transmission at the level of the dorsal horn of the spinal cord. This modulation is achieved via two channels: the α‐Amino‐3‐hydroxy‐5‐methyl‐4‐isoxazolepropionic acid (AMPA) and NMDA receptors. Initially, the AMPA channel controls the transmission of stimuli of mild–moderate severity. Once the AMPA channel reaches its limit of membrane depolarization, the NMDA channel is activated and facilitates the transmission of painful stimuli in a progressive fashion leading to central sensitization and glial activation. At the level of pharmacogenomics, the metabolism of each opioid is patient‐specific. Glucuronidation is unique for the metabolism of morphine, hydromorphone, and oxymorphone. The metabolism of all other opioids requires specific Cytochrome P450 (CYP) isoenzymes. The activity of each isoenzyme and the activity of the metabolites of each opioid vary among patients depending on their genetic makeup and coexistent environmental factors such as the use of other medications that may enhance or inhibit the CYP isoenzyme activity.Keywords
This publication has 74 references indexed in Scilit:
- Mortality in Adults With Sickle Cell Disease and Pulmonary HypertensionJAMA, 2012
- Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Codeine Therapy in the Context of Cytochrome P450 2D6 (CYP2D6) GenotypeClinical Pharmacology & Therapeutics, 2011
- Leg ulcers in sickle cell diseaseAmerican Journal of Hematology, 2010
- The risks and benefits of long‐term use of hydroxyurea in sickle cell anemia: A 17.5 year follow‐upAmerican Journal of Hematology, 2010
- Allogeneic Hematopoietic Stem-Cell Transplantation for Sickle Cell DiseaseNew England Journal of Medicine, 2009
- Pain site frequency and location in sickle cell disease: The PiSCES projectPain, 2009
- Central Sensitization: A Generator of Pain Hypersensitivity by Central Neural PlasticityThe Journal of Pain, 2009
- Opioid MetabolismMayo Clinic Proceedings, 2009
- The Effect of CYP2D6 Polymorphisms on the Response to Pain Treatment for Pediatric Sickle Cell Pain CrisisThe Journal of Pediatrics, 2007
- Molecular tinkering of G protein‐coupled receptors: an evolutionary successThe EMBO Journal, 1999